



QUANTUM BIOPHARMA —

Groundbreaking R&D meets world-class
product development and commercialization

NASDAQ: QNTM

Sidoti Micro Cap Conference

May 21, 2025

Forward Looking Statements

This Presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company, contains “forward looking information” and “forward looking statements” (forward looking information within the meaning of applicable securities laws). Forward looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, capital structure, plans and objectives, and other statements that are not historical facts. In some cases, forward looking information can be identified by the use of forward looking terminology such as “plans,” “targets,” “does not expect,” “is expected,” “an opportunity exists,” “budget,” “scheduled,” “estimates,” “outlook,” “forecasts,” “projection,” “prospects,” “intends,” “anticipates,” “does not anticipate,” “believes,” “may,” and other similar words or variations of such words. Statements containing forward looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

The forward looking information included in this Presentation includes, among other things, statements relating to the design, timing and cost of the Company’s drug candidates and clinical trials; key milestones relating to clinical and regulatory developments; potential market demand for the Company’s drug candidates; near term capital requirements; the anticipated patent and trademark exclusivity periods for the Company’s drug candidates; and the potential role of the Company’s drug candidates in the treatment of Multiple Sclerosis and other inflammatory and degenerative neurological disorders and other orphan diseases. The forward looking information in this Presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances.

Despite a careful process to prepare and review the forward looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. The forward looking information in this Presentation is based on a number of assumptions that include, but are not limited to, the following: the Company’s ability to generate sufficient cash flow from operations and obtain financing, if needed, on acceptable terms or at all; the general economic, financial market, regulatory and political conditions in which the Company operates; the interest of potential purchasers in the Company’s drug candidates; anticipated and unanticipated costs; the government regulation of the Company’s activities and drug candidates; the timely receipt of any required regulatory approvals and authorizations and the continuation of previously received regulatory approvals and authorizations; the Company’s ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; the Company’s ability to conduct operations in a safe, efficient and effective manner; and the Company’s expansion plans and timeframe for completion of such plans.

Agenda:

Company Overview

LUCID-21-302

unbuzzd™

REKVRV™

Financial Updates

Closing Summary

On the Call Today:



Jason Sawyer

Head of Finance and M&A

- Veteran financier, leading Bahamas-based alternative investment and advisory firm Access Alternative Group S.A. for more than 20 years
- Completed over \$5 billion of capital placement spanning leading global alternative fund managers, capital formation and investment in private and public startups, early-stage growth companies, as well as targeted M&A across various sectors
- Jason sits on various corporate boards and advisory committees

Corporate Overview

Quantum BioPharma is an R&D focused biopharmaceutical company led by a world-class science team dedicated to developing innovative, novel therapies for neurodegenerative disease and alcohol misuse.

- Proprietary R&D conducted by a world-class team of medicinal chemists and pharmaceutical industry professionals

- Dr. Lakshmi P. Kotra, B.Pharm.(Hons), PhD – Director
- Dr. Andrzej Chruscinski, MD, PhD – Vice President, Clinical and Scientific Affairs
- Dr. Eric Hoskins – Director
- Ashwini Joshi, MS, PG Diploma (QA&RA) - Director-Pharmaceutical Development



NASDAQ
QNTM

Share Price¹ US\$12.26

Market Cap¹ US\$33.23M

Shares Outstanding² 2.711M

Float 1.40M

Cash & Cash Equivalents² US\$11.16M

1) As of May 19, 2025
2) As of Dec 31, 2024

LUCID MS

- LUCID MS - **Potential multi-billion asset** in demyelinating diseases, with initial indication in multiple sclerosis (MS)
- Proprietary R&D conducted by a **world-class team** of medicinal chemists and pharmaceutical industry professionals

unbuzzd™ + REKVR™

- unbuzzd™, a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick for this fast-growing consumer product category, **launched in 2024 and expected to grow 300% by 2030**
- REKVR™ a formulation under development for an alcohol misuse treatment for use in emergency and hospital settings, an unmet need and has potential for **exponential growth**
- Owned by licensee Celly Nu - led by **CPG market veterans** with a proven track record of launching and scaling consumer product distribution programs while increasing company valuation by as much as 35-fold

LUCID-21-302: A Potential First-In-Class Approach to Treating Demyelinating Diseases

- **New Chemical Entity** discovered by Dr. Kotra and team at University Health Network
- Mouse models of MS showed **accelerated** functional recovery, **preserved** myelin, and **reduced** axonal degeneration
- First therapy with the potential to **reduce** demyelination and **preserve** neuronal health
- Over 14 years of preclinical R&D showed **promising efficacy**
- **No suppression** of immune system and **no immunomodulation**
- Phase 1 Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) studies evaluating the safety and tolerability of Lucid-21-302 in multiple respective cohorts have been completed, with **no serious drug-related effects**
- **Potentially Expedited pathway** to market, with Phase 2 clinical trial on the horizon

	Discovery	Lead	In vivo PoC	IND* enabling studies	P1	P2	P3	Market Launch
LUCID-21-302 (Multiple Sclerosis)					Phase 1 SAD/MAD Completed	Phase 2 Q1 2026 Estimated		

KOL's predict that neuroprotective therapies are going to be the top priority for new treatments in the future of MS¹

Revolutionary technology for alcohol intoxication



	Formulation Development	Regulatory Compliance	Final Composition	Technology Transfer/Commercialization	Clinical Trial	Market Launch
unbuzzd™ (Recreational alcohol misuse treatment)						Q3 2024

- Licensee Celly Nutrition Corporation, has an exclusive, perpetual license for the consumer market
- Multi-Channel Distribution Strategy
- Launch with FUSION Distribution across Puerto Rico
- Launch with AATAC
- Expand e-commerce to TikTok Shop, IHerb, and other strategic platforms
- Launch Affiliate and Ambassador Programs
- Launch new 1-pack box packed in an 8-pack display box for retail display on the counter near the register
- Following highly positive results from unbuzzd Clinical Study, Celly Nutrition has engaged a leading New York investment bank to *pursue an IPO on a major US public exchange*

REKVRYPM

REKVRYPM is an innovative and proven treatment to shorten the alcohol intoxication patient journey



	Formulation Development	Regulatory Compliance	Final Composition	Technology Transfer/ Commercialization	Clinical Trial	Market Launch
REKVRYPM (Hospital and emergency settings alcohol misuse treatment)						

- Quantum BioPharma developed and owns the IP and retains 100% rights for all medical and pharmaceutical applications of this alcohol misuse treatment.
- Successful REKVRYPM Clinical Trial announced February 2025 Key Findings: Accelerated Alcohol Metabolism; Rapid Improvements in Alertness; Rapid Improvements in Physiologic Changes due to Intoxication; Reduced Perceived Impairment and Mental Fatigue; Hangover Relief; No Side Effects
- Compelling solution in clinical settings for patients as Alcohol Intoxication in U.S. Emergency Departments (ED)1 experienced ~3.0M Total Alcohol-Related ED Visits in 2024, driving overcrowding in the ED.
- Tremendous revenue potential without the marketing cost burden.

1) Based on research from EVERSANA Opportunity Assessment

2024 Financial Statements Aligned to Strategy

- Strong improvements in cash, working capital, operating efficiency and the removal of material uncertainty related to going concern**

- Operating expenses reduced to \$16.1M USD in FY'24 compared to \$23.8M USD in FY'23, an improvement of over 32%.
- Net cash used in operations of \$6.9M USD compared to \$10.8M USD in FY 2023, an improvement of 36%.
- Accounts payable have been significantly reduced from \$4.4 million USD at December 31, 2024, to less than \$1M USD at the end of March 2025.
- G&A expenses increased to \$9.4M in FY'24 compared to \$9.0M in FY'23 due to advancing key clinical assets.
- Sufficient working capital to carry out operations for FY'25 & sufficient cash on hand to sustain basic operations beyond January 2027.
- Strong balance sheet and overall progress enabled Company to remove its Material Uncertainty Related to Going Concern.

\$ in Thousands	Year Ended December 31,	
	2024	2023
Operating Expenses:		
General & Administrative	\$ 9,410	\$ 9,033
Research & Development	6,083	3,859
Share-Based Payments	152	3,835
Depreciation & Amortization	491	2,506
Impairment Loss	-	4,556
Total Operating Expenses	16,136	23,789
Loss from Operations	(16,136)	(23,789)
Net loss	\$ (14,916)	\$ (18,231)

\$ in Thousands	December 31, 2024	December 31, 2023
Cash & Cash Equivalents, and Current Assets	\$ 12,053	\$ 11,085

Closing Summary

Robust portfolio and pipeline focused on addressing significant unmet needs in brain disorders and alcohol health

- Led by a **world-class** R&D team and seasoned commercial experts
- **LUCID MS**, a potential **multi-billion asset** in demyelinating diseases, with an initial indication in MS, and an expedited path to market
 - **100% exclusive** worldwide patent rights to NCE for treatment of multiple sclerosis and other demyelinating disease
- **unbuzzd™**, a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick and RTD beverage for this fast-growing consumer product category, launched in 2024 and expected to grow 300% by 2030
 - **7% royalty** on gross revenue of unbuzzd™, with no burden of marketing and operations costs
 - **25% equity stake** in Celly Nu, a public non-listed Canadian company formed in 2023 focused exclusively on unbuzzd™
 - **Completed a clinical trial** with results of data analysis showing definitively that unbuzzd™ accelerated the rate at which BAC was reduced in study subjects
 - Following highly positive results from unbuzzd Clinical Study, **Celly Nutrition is pursuing an IPO on a major US public exchange**
- **REKVRy™** a formulation for alcohol misuse treatment for use in emergency and hospital settings, an unmet need and has potential for **exponential growth**
 - **100% rights** to REKVRy™, any and all medical and pharmaceutical applications of alcohol misuse treatment
- Strong improvements in cash, working capital, operating efficiency and the removal of material uncertainty related to going concern



Company

Jason Sawyer
Head of Finance and M&A
jsawyer@quantumbiopharma.com
+1-855-971-3121

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us

Q&A

NASDAQ: QNTM

quantumbiopharma.com